Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
32
CZMWF Quote, Financials, Valuation and Earnings
Last price:
$47.00
Seasonality move
:
8.35%
Day range:
$47.00 - $47.00
52-week range:
$45.51 - $70.88
Dividend yield:
1.38%
P/E ratio:
26.21x
P/S ratio:
1.67x
P/B ratio:
4.59x
Volume:
45
Avg. volume:
66
1-year change:
-6.86%
Market cap:
$4.1B
Revenue:
$2.5B
EPS (TTM):
$1.79
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CZMWF
Carl Zeiss Meditec AG
|
-- | -- | -- | -- | -- |
|
BNTX
BioNTech SE
|
$1.2B | $0.12 | -24.04% | -86.85% | $138.33 |
|
CVAC
CureVac NV
|
$25.1M | -$0.08 | 0.04% | -32.36% | $5.31 |
|
IFRX
InflaRx NV
|
$34.6K | -$0.14 | -74.55% | -16.09% | $11.24 |
|
IMTX
Immatics NV
|
$12.5M | -$0.45 | -81.87% | -704.25% | $18.75 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CZMWF
Carl Zeiss Meditec AG
|
$47.00 | -- | $4.1B | 26.21x | $0.65 | 1.38% | 1.67x |
|
BNTX
BioNTech SE
|
$91.46 | $138.33 | $22B | 191.55x | $0.00 | 0% | 6.22x |
|
CVAC
CureVac NV
|
$4.28 | $5.31 | $963.7M | 5.99x | $0.00 | 0% | 11.89x |
|
IFRX
InflaRx NV
|
$1.06 | $11.24 | $71.8M | -- | $0.00 | 0% | 327.52x |
|
IMTX
Immatics NV
|
$9.57 | $18.75 | $1.2B | 42.21x | $0.00 | 0% | 12.78x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CZMWF
Carl Zeiss Meditec AG
|
-- | -0.029 | -- | 1.10x |
|
BNTX
BioNTech SE
|
1.31% | 1.267 | 1.22% | 6.78x |
|
CVAC
CureVac NV
|
3.87% | 1.835 | 3.39% | 1.84x |
|
IFRX
InflaRx NV
|
2.1% | -0.453 | 1.26% | 2.34x |
|
IMTX
Immatics NV
|
3.78% | 2.023 | 1.86% | 6.97x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CZMWF
Carl Zeiss Meditec AG
|
$328.5M | $60.2M | 7.37% | 7.44% | 8.67% | $108.3M |
|
BNTX
BioNTech SE
|
$1.6B | $743.4M | -2.96% | -3.01% | 41.89% | $785.5M |
|
CVAC
CureVac NV
|
$57.9M | -$11.6M | 19.52% | 20.55% | -18.33% | $31.6M |
|
IFRX
InflaRx NV
|
-$89.2K | -$11.7M | -80.95% | -82.01% | -42057.91% | -$11.4M |
|
IMTX
Immatics NV
|
-- | -$63.9M | -24.18% | -25.21% | -1053.82% | -$56.2M |
Carl Zeiss Meditec AG vs. Competitors
-
Which has Higher Returns CZMWF or BNTX?
BioNTech SE has a net margin of 5.16% compared to Carl Zeiss Meditec AG's net margin of -1.89%. Carl Zeiss Meditec AG's return on equity of 7.44% beat BioNTech SE's return on equity of -3.01%.
Company Gross Margin Earnings Per Share Invested Capital CZMWFCarl Zeiss Meditec AG52.71% $0.36 $2.3B BNTXBioNTech SE90.24% -$0.14 $22B -
What do Analysts Say About CZMWF or BNTX?
Carl Zeiss Meditec AG has a consensus price target of --, signalling downside risk potential of --. On the other hand BioNTech SE has an analysts' consensus of $138.33 which suggests that it could grow by 51.25%. Given that BioNTech SE has higher upside potential than Carl Zeiss Meditec AG, analysts believe BioNTech SE is more attractive than Carl Zeiss Meditec AG.
Company Buy Ratings Hold Ratings Sell Ratings CZMWFCarl Zeiss Meditec AG0 0 0 BNTXBioNTech SE14 5 0 -
Is CZMWF or BNTX More Risky?
Carl Zeiss Meditec AG has a beta of 1.213, which suggesting that the stock is 21.25% more volatile than S&P 500. In comparison BioNTech SE has a beta of 1.295, suggesting its more volatile than the S&P 500 by 29.477%.
-
Which is a Better Dividend Stock CZMWF or BNTX?
Carl Zeiss Meditec AG has a quarterly dividend of $0.65 per share corresponding to a yield of 1.38%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Carl Zeiss Meditec AG pays 29.83% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. Carl Zeiss Meditec AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CZMWF or BNTX?
Carl Zeiss Meditec AG quarterly revenues are $623.3M, which are smaller than BioNTech SE quarterly revenues of $1.8B. Carl Zeiss Meditec AG's net income of $32.2M is higher than BioNTech SE's net income of -$33.5M. Notably, Carl Zeiss Meditec AG's price-to-earnings ratio is 26.21x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carl Zeiss Meditec AG is 1.67x versus 6.22x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CZMWFCarl Zeiss Meditec AG1.67x 26.21x $623.3M $32.2M BNTXBioNTech SE6.22x 191.55x $1.8B -$33.5M
-
Which has Higher Returns CZMWF or CVAC?
CureVac NV has a net margin of 5.16% compared to Carl Zeiss Meditec AG's net margin of -5832.47%. Carl Zeiss Meditec AG's return on equity of 7.44% beat CureVac NV's return on equity of 20.55%.
Company Gross Margin Earnings Per Share Invested Capital CZMWFCarl Zeiss Meditec AG52.71% $0.36 $2.3B CVACCureVac NV91.57% $1.41 $1.1B -
What do Analysts Say About CZMWF or CVAC?
Carl Zeiss Meditec AG has a consensus price target of --, signalling downside risk potential of --. On the other hand CureVac NV has an analysts' consensus of $5.31 which suggests that it could grow by 24.37%. Given that CureVac NV has higher upside potential than Carl Zeiss Meditec AG, analysts believe CureVac NV is more attractive than Carl Zeiss Meditec AG.
Company Buy Ratings Hold Ratings Sell Ratings CZMWFCarl Zeiss Meditec AG0 0 0 CVACCureVac NV1 3 0 -
Is CZMWF or CVAC More Risky?
Carl Zeiss Meditec AG has a beta of 1.213, which suggesting that the stock is 21.25% more volatile than S&P 500. In comparison CureVac NV has a beta of 1.771, suggesting its more volatile than the S&P 500 by 77.063%.
-
Which is a Better Dividend Stock CZMWF or CVAC?
Carl Zeiss Meditec AG has a quarterly dividend of $0.65 per share corresponding to a yield of 1.38%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Carl Zeiss Meditec AG pays 29.83% of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend. Carl Zeiss Meditec AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CZMWF or CVAC?
Carl Zeiss Meditec AG quarterly revenues are $623.3M, which are larger than CureVac NV quarterly revenues of $63.3M. Carl Zeiss Meditec AG's net income of $32.2M is lower than CureVac NV's net income of $319.3M. Notably, Carl Zeiss Meditec AG's price-to-earnings ratio is 26.21x while CureVac NV's PE ratio is 5.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carl Zeiss Meditec AG is 1.67x versus 11.89x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CZMWFCarl Zeiss Meditec AG1.67x 26.21x $623.3M $32.2M CVACCureVac NV11.89x 5.99x $63.3M $319.3M
-
Which has Higher Returns CZMWF or IFRX?
InflaRx NV has a net margin of 5.16% compared to Carl Zeiss Meditec AG's net margin of -51538.49%. Carl Zeiss Meditec AG's return on equity of 7.44% beat InflaRx NV's return on equity of -82.01%.
Company Gross Margin Earnings Per Share Invested Capital CZMWFCarl Zeiss Meditec AG52.71% $0.36 $2.3B IFRXInflaRx NV-320.86% -$0.21 $54.4M -
What do Analysts Say About CZMWF or IFRX?
Carl Zeiss Meditec AG has a consensus price target of --, signalling downside risk potential of --. On the other hand InflaRx NV has an analysts' consensus of $11.24 which suggests that it could grow by 960.74%. Given that InflaRx NV has higher upside potential than Carl Zeiss Meditec AG, analysts believe InflaRx NV is more attractive than Carl Zeiss Meditec AG.
Company Buy Ratings Hold Ratings Sell Ratings CZMWFCarl Zeiss Meditec AG0 0 0 IFRXInflaRx NV5 2 0 -
Is CZMWF or IFRX More Risky?
Carl Zeiss Meditec AG has a beta of 1.213, which suggesting that the stock is 21.25% more volatile than S&P 500. In comparison InflaRx NV has a beta of 1.459, suggesting its more volatile than the S&P 500 by 45.896%.
-
Which is a Better Dividend Stock CZMWF or IFRX?
Carl Zeiss Meditec AG has a quarterly dividend of $0.65 per share corresponding to a yield of 1.38%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Carl Zeiss Meditec AG pays 29.83% of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend. Carl Zeiss Meditec AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CZMWF or IFRX?
Carl Zeiss Meditec AG quarterly revenues are $623.3M, which are larger than InflaRx NV quarterly revenues of $27.8K. Carl Zeiss Meditec AG's net income of $32.2M is higher than InflaRx NV's net income of -$14.3M. Notably, Carl Zeiss Meditec AG's price-to-earnings ratio is 26.21x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carl Zeiss Meditec AG is 1.67x versus 327.52x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CZMWFCarl Zeiss Meditec AG1.67x 26.21x $623.3M $32.2M IFRXInflaRx NV327.52x -- $27.8K -$14.3M
-
Which has Higher Returns CZMWF or IMTX?
Immatics NV has a net margin of 5.16% compared to Carl Zeiss Meditec AG's net margin of -974.45%. Carl Zeiss Meditec AG's return on equity of 7.44% beat Immatics NV's return on equity of -25.21%.
Company Gross Margin Earnings Per Share Invested Capital CZMWFCarl Zeiss Meditec AG52.71% $0.36 $2.3B IMTXImmatics NV-- -$0.49 $508.8M -
What do Analysts Say About CZMWF or IMTX?
Carl Zeiss Meditec AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Immatics NV has an analysts' consensus of $18.75 which suggests that it could grow by 95.93%. Given that Immatics NV has higher upside potential than Carl Zeiss Meditec AG, analysts believe Immatics NV is more attractive than Carl Zeiss Meditec AG.
Company Buy Ratings Hold Ratings Sell Ratings CZMWFCarl Zeiss Meditec AG0 0 0 IMTXImmatics NV9 0 0 -
Is CZMWF or IMTX More Risky?
Carl Zeiss Meditec AG has a beta of 1.213, which suggesting that the stock is 21.25% more volatile than S&P 500. In comparison Immatics NV has a beta of 1.361, suggesting its more volatile than the S&P 500 by 36.134%.
-
Which is a Better Dividend Stock CZMWF or IMTX?
Carl Zeiss Meditec AG has a quarterly dividend of $0.65 per share corresponding to a yield of 1.38%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Carl Zeiss Meditec AG pays 29.83% of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend. Carl Zeiss Meditec AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CZMWF or IMTX?
Carl Zeiss Meditec AG quarterly revenues are $623.3M, which are larger than Immatics NV quarterly revenues of $6.1M. Carl Zeiss Meditec AG's net income of $32.2M is higher than Immatics NV's net income of -$59.1M. Notably, Carl Zeiss Meditec AG's price-to-earnings ratio is 26.21x while Immatics NV's PE ratio is 42.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carl Zeiss Meditec AG is 1.67x versus 12.78x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CZMWFCarl Zeiss Meditec AG1.67x 26.21x $623.3M $32.2M IMTXImmatics NV12.78x 42.21x $6.1M -$59.1M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
55
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
35
SMX alert for Dec 19
SMX (Security Matters) Plc [SMX] is up 24.85% over the past day.
Sell
36
INSP alert for Dec 19
Inspire Medical Systems, Inc. [INSP] is down 19.66% over the past day.
Sell
40
INSM alert for Dec 19
Insmed, Inc. [INSM] is down 16.08% over the past day.
